PROK
HEALTHCAREProKidney Corp - Class A
$1.96+0.04 (+2.08%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving PROK Today?
No stock-specific AI insight has been generated for PROK yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.54$5.95
$1.96
Fundamentals
Market Cap$592M
P/E Ratio—
EPS$-0.52
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume581K
Avg Volume (10D)—
Shares Outstanding142.0M
PROK News
20 articles- 3 Promising Penny Stocks With Market Caps Up To $600MYahoo Finance·May 6, 2026
- ProKidney (PROK) Appoints Greg Madison as CCO to Lead Commercial Strategy for RilparencelYahoo Finance·May 1, 2026
- April 2026 Penny Stock HighlightsYahoo Finance·Apr 3, 2026
- What Makes ProKidney Corp. (PROK) So AttractiveYahoo Finance·Mar 31, 2026
- ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial OfficerYahoo Finance·Mar 25, 2026
- ProKidney Reports Full Year 2025 Financial Results and Business HighlightsYahoo Finance·Mar 18, 2026
- Korro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue EstimatesYahoo Finance·Mar 12, 2026
- Aquestive Therapeutics (AQST) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 4, 2026
- 3 Promising Penny Stocks With At Least $600M Market CapYahoo Finance·Feb 12, 2026
- 3 Penny Stocks With Market Caps Under $700MYahoo Finance·Jan 8, 2026
- ProKidney to Present at the 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Jan 6, 2026
- ProKidney Corp. (PROK) Positioned to Redefine Chronic Kidney Disease Treatment, Believes H.C. WainwrightYahoo Finance·Dec 27, 2025
- Promising Penny Stocks To Watch In December 2025Yahoo Finance·Dec 2, 2025
- While insiders own 18% of ProKidney Corp. (NASDAQ:PROK), retail investors are its largest shareholders with 50% ownershipYahoo Finance·Nov 23, 2025
- ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical UpdatesYahoo Finance·Nov 10, 2025
- ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025Yahoo Finance·Nov 6, 2025
- ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare ConferenceYahoo Finance·Oct 29, 2025
- Discovering Potential: IZEA Worldwide And 2 Other Top Penny StocksYahoo Finance·Oct 13, 2025
- ProKidney Corp (PROK) Touts Reparencel Therapy for GrowthYahoo Finance·Sep 20, 2025
- ProKidney Leads Our Trio Of Promising Penny StocksYahoo Finance·Sep 12, 2025
All 20 articles loaded
Price Data
Open$1.95
Previous Close$1.92
Day High$1.99
Day Low$1.87
52 Week High$5.95
52 Week Low$0.54
52-Week Range
$0.54$5.95
$1.96
Fundamentals
Market Cap$592M
P/E Ratio—
EPS$-0.52
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume581K
Avg Volume (10D)—
Shares Outstanding142.0M
About ProKidney Corp - Class A
ProKidney Corporation. The company is headquartered in Winston-Salem, North Carolina.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—